What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s like semaglutide (active ingredient in Ozempic/Wegovy) and tirzepatide (active ingredient in Mounjaro/Zepbound) has been complex and evolving. Here's a breakdown:

What Happened with the FDA and Compounded GLP-1s?

1. Surge in Demand & Shortages:

   • The immense popularity of FDA-approved GLP-1 medications for weight loss and type 2 diabetes led to significant shortages of the branded products (Ozempic, Wegovy, Mounjaro, Zepbound).

2. Compounding Pharmacies Stepped In:

   • Under federal law (the Drug Quality and Security Act, or DQSA), compounding pharmacies can legally create compounded versions of drugs that are on the FDA's official drug shortage list, provided they use an FDA-approved active pharmaceutical ingredient (API).
   • Many pharmacies and clinics began offering compounded semaglutide and tirzepatide to meet demand.

3. FDA's Concerns and Warnings:

   • Unapproved Salt Forms: The FDA issued strong warnings because many compounding pharmacies were using semaglutide sodium or semaglutide acetate as their active ingredient. The FDA-approved drugs (Ozempic, Wegovy) contain semaglutide base. The FDA explicitly stated that these salt forms are not the same as the active ingredient in the approved drugs, and their safety and effectiveness have not been established. This was a major point of contention.
   • Lack of FDA Approval: The FDA reiterated that compounded drugs are not FDA-approved. This means they haven't undergone the rigorous review process for safety, efficacy, and quality that branded medications have.
   • Safety and Quality Risks: The FDA raised concerns about potential impurities, incorrect dosages, and lack of sterility in some compounded products, leading to reports of adverse events.
   • Misleading Marketing: Some clinics and pharmacies were marketing their compounded products as "bioidentical" or "identical" to the FDA-approved drugs, which the FDA considers misleading and false.
   • Enforcement Actions: The FDA sent warning letters and cease-and-desist letters to specific companies and clinics selling unapproved or illegally compounded GLP-1 products. They also collaborated with state boards of pharmacy to address violations.

4. The "Drug Shortage List" Nuance:

   • While semaglutide and tirzepatide have been on the FDA's drug shortage list, allowing for legitimate compounding under specific conditions, the key was what API was being used and how it was compounded.

Who is Still Operating Legally?

Legally operating compounding pharmacies must adhere to strict federal and state regulations. Here's what makes them legal:

1. Using an FDA-Approved Active Pharmaceutical Ingredient (API):

   • For semaglutide, this means using semaglutide base, not semaglutide sodium or acetate.
   • For tirzepatide, it means using the API that matches the FDA-approved version.
   • The API itself must be sourced from an FDA-registered facility.

2. Compounding When a Drug is on the FDA's Drug Shortage List:

   • Compounding is generally allowed for a patient with a specific prescription when the commercial drug is unavailable due to shortage.

3. Operating as a Licensed Compounding Pharmacy:

   • 503A Compounding Pharmacies: These are traditional pharmacies that compound drugs for individual patient prescriptions. They are regulated primarily by state boards of pharmacy. They must follow U.S. Pharmacopeia (USP) standards for compounding.
     • What to look for: They require a valid, patient-specific prescription from a licensed healthcare provider, and they should be able to confirm they are using FDA-approved API (semaglutide base, for example) and sourcing it from a reputable supplier.
   • 503B Outsourcing Facilities: These are larger facilities that can compound in bulk without individual patient prescriptions before receiving them, to be distributed to hospitals or clinics. They must register with the FDA and are subject to FDA inspections, following stricter Current Good Manufacturing Practice (cGMP) regulations.
     • What to look for: These facilities are more heavily regulated and transparent about their FDA registration. They also must adhere to the same API and drug shortage rules.

Specific Brands/Services:

It's difficult to recommend "brands" of compounded GLP-1s because compounded drugs are not branded in the traditional sense like Ozempic or Wegovy. Instead, you're looking for a reputable, licensed compounding pharmacy that meets the legal criteria:

• Ask your prescribing doctor: Your doctor should be able to refer you to a reputable compounding pharmacy they trust, which adheres to all FDA and state guidelines.
• Verify the Pharmacy's License: You can check with your state's Board of Pharmacy to ensure any compounding pharmacy is currently licensed and in good standing.
• Ask Direct Questions: If considering a compounded GLP-1, always ask the pharmacy:
  • "What is the active ingredient you are using (e.g., semaglutide base or a salt form)?"
  • "Where do you source your active pharmaceutical ingredient (API)?"
  • "Are you a 503A compounding pharmacy or a 503B outsourcing facility?"

In summary: While the FDA allows compounding of GLP-1s under specific circumstances (drug shortage, FDA-approved API), they strongly advise against using compounded versions that contain unapproved salt forms or come from facilities not adhering to strict quality and safety standards. Always prioritize the FDA-approved branded medications if available and affordable. If considering a compounded option, choose wisely by ensuring the pharmacy is fully compliant with all regulations and transparent about its ingredients and processes.